

Reference	Investigator	Investigator's Title/Role	Title of Research Project	Business Entity	Nature of Financial Interest	Approximate Dollar Value
CRV_00000931	Philip Bernard	Associate Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF BREAST CANCER	Bioclassifier	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00001547	Agnes Ostafin	Research Associate Professor and Principal Investigator	RETRIEVABLE BLOOD OXYGEN CARRIER SYSTEM BRIDGE FUNDS	Nanoshell Company, LLC	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00002616	Vicente Planelles	Professor and Co-Investigator	Analysis of Latent HIV-1 Infection in Peripheral Blood Lymphocytes of Aviremic HIV-1 Infected Patients	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00002816	Anne Blaschke	Associate Professor and Principal Investigator	PCR-Based Identification of Pathogenic Organisms from Blood Culture and CSF	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00002858	Gerald Krueger	Professor and Co-Investigator	Abbott Fellowship 2014	Abbott Pharmaceutical	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00002886	Anne Blaschke	Associate Professor and Principal Investigator	PCR for the Diagnosis of Bloodstream Infection in the NICU	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00002888	Carrie Byington	Professor and Co-Investigator	PCR for the Diagnosis of Bloodstream Infection in the NICU	N/A	Royalty income from Intellectual Property	\$5,000-9,999
CRV_00003061	Anne Blaschke	Associate Professor and Co-Investigator	Epidemiology and Etiology of Hospitalized Pneumonia in Children	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00003062	Carrie Byington	Professor and Co-Investigator	Epidemiology and Etiology of Hospitalized Pneumonia in Children	N/A	Royalty income from Intellectual Property	\$5,000-9,999
CRV_00003240	Alberto Bosque	Research Assistant Professor and Principal Investigator	Reactivation of latent HIV through TLR signaling	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00003514	Richard Cawthon	Research Associate Professor and Co-Investigator	The Utah study of Fertility, Longevity and Aging	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00003523	Christopher Peters	Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Royalty income from Intellectual Property	>\$100,000
CRV_00003523	Christopher Peters	Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Income for Educational Courses	\$20,000-39,999
CRV_00003785	Siam Oottamasathien	Associate Professor and Principal Investigator	Mechanisms for Bladder Inflammation and Fibrosis	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00003879	Anne Blaschke	Associate Professor and Principal Investigator	Real-Time Multiplex PCR for Diagnosis of Bacterial and Viral Infections in Children	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00003880	Carrie Byington	Professor and Co-Investigator	Real-Time Multiplex PCR for Diagnosis of Bacterial and Viral Infections in Children	N/A	Royalty Income from Intellectual Property	\$5,000-9,999
CRV_00004124	Edward Dudek	Professor and Principal Investigator	TARGETED INTERNEURON ABLATION AND EPILEPTOGENESIS	Epitel	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00004125	Edward Dudek	Professor and Principal Investigator	IVERMECTIN ACTIVATED HUMAN GLYCINE RECEPTOR SUPPRESSION OF PHARMACORESISTENT EPILEPSY	Epitel	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00004422	Paul LaStayo	Professor and Co-Investigator	Reducing Falls with RENEW in Older Adults Who Have Fallen	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00004481	Bradley Katz	Professor and Principal Investigator	Thin film spectacle coatings to reduce light sensitivity and headaches in child and adolescent patients with migraine	Axon Optics, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00004729	Dan Kadmas	Professor and Co-Investigator	Multi-Tracer PET Assessment of Primary Brain Tumors	MultiFunctional Imaging, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00004733	Christopher Peters	Professor and Co-Investigator	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System	Biomet	Royalty Income from Intellectual Property	>\$100,000
CRV_00004733	Christopher Peters	Professor and Co-Investigator	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System	Biomet	Income for Consulting/Education/Spreading	\$20,000-39,999
CRV_00004997	Howard Colman	Professor and Principal Investigator	Alliance A071101 >> A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, Alliance IND# 15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectabl	Hoffman La Roche	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00005106	Michael Esplin	Professor and Co-Investigator	Genomic and Proteomic Network for Preterm Birth Research: Case Control Study	Sera Prognostics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00005108	Michael Esplin	Professor and Co-Investigator	Genomics and Proteomics Network for Preterm Birth: Expression Profiling Study	Sera Prognostics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00005110	Michael Esplin	Professor and Co-Investigator	Genomics and Proteomics Network for Preterm Birth Research: Longitudinal Study	Sera Prognostics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00005449	Roy Bloebaum	Research Professor and Principal Investigator	PREVENTION OF BIOFILM RELATED INFECTIONS USING A NOVEL, BROAD SPECTRUM ANTIMICROBIAL COATING, CSA-13, ON ORTHOPEDIC FIXATION PLATES	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00005860	Stephane Meystre	Assistant Professor and Principal Investigator	Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record	Clinacuity	CEO/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00005943	Greg Jones	Faculty and Co-investigator	Automated Problem and Allergy Lists Enrichment Based on High Accuracy Information Extraction from the Electronic Health Record	Clinacuity	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006229	Florian Solzbacher	Professor and Co-Investigator	Revolutionizing Utah Array using Nanotechnology to Enhance Efficacy and Longevity	Blackrock Microsystems	Income for Consulting	>\$100,000
CRV_00006229	Florian Solzbacher	Professor and Co-Investigator	Revolutionizing Utah Array using Nanotechnology to Enhance Efficacy and Longevity	Blackrock Microsystems	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006252	Manoranjan Misra	Professor and Principal Investigator	Rapid Diagnosis of Tuberculosis at the Point of Care Using a Handheld Volatile Biomarker Sensor	NANOSYNTH MATERIALS AND SENSORS INC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006267	Sung Wan Kim	Professor and Principal Investigator	Design of Oncolytic Adenovirus Conjugated with Novel Polymer for Cancer Treatment	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006312	Siam Oottamasathien	Associate Professor and Principal Investigator	Treatment of Bladder Pain by Novel Glycosaminoglycan Derivatives	Glycomira Therapeutics	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006313	Glenn Prestwich	Professor and Co-Investigator	Treatment of Bladder Pain by Novel Glycosaminoglycan Derivatives	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006569	Carl Thummel	Professor and Principal Investigator	Regulation of Metabolism in Drosophila	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00006796	Glenn Prestwich	Professor and Principal Investigator	Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00007427	Christopher Pelt	Associate Professor and Principal Investigator	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System Early Intraoperative & Candidacy Assessment	Biomet	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00007441	Eugene Kholmovski	Research Assistant Professor and Principal Investigator	Cardiac MRI Techniques for Atrial Fibrillation Research and Management	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00007657	Christopher Pelt	Associate Professor and Co-Investigator	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System	Biomet	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Vascular Biologics Limited	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Facilitate of IDE	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Amgen	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Abbott Pharmaceutical	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Centocor	Income for Consulting/Education/Sp eaking	\$20,000-39,999
CRV_00008094	Gerald Krueger	Professor and Co-Investigator	Efficacy of Ustekinumab (Anti-IL-12/23) followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris Protocol ITN059AI (Pause Study) Version 2.0 30SEP2013	Novartis	Income for Consulting/Education/Sp eaking	\$5,000-9,999

CRV_00008243	Balamurali Ambati	Professor and Principal Investigator	Intracaptor Interference of VEGF in Ocular Angiogenesis	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00008445	David Krizaj	Professor and Principal Investigator	The role of mechanosensation in the vertebrate retina	Asha Vision, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00008593	James Beck	Adjunct Assistant Professor and Co-Investigator	Safety Study of Percutaneous Osseointegrated Iplants for Prosthetic Attachment-Stuart IPA	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00008722	Paul LaStayo	Professor and Co-Investigator	The effect of a novel nutritional and contractile countermeasure on the regulation of protein synthesis in older adults with hip fracture	N/A	Intellectual Property	\$10,000-19,999
CRV_00008800	Howard Colman	Professor and Co-Investigator	GSK EGF111767: An Open-Label, Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination with other Anticancer Treatment in Patients with Solid Tumors	Hoffman La Roche/Genetech	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00009194	Sancy Leachman	Adjunct Professor and Co-Investigator	Molecular Classifications of Cancer	Myriad Genetics	Income for Consulting	\$5,000-9,999
CRV_00009230	Sancy Leachman	Adjunct Professor and Co-Investigator	Cancer Genetics Study	Myriad Genetics	Income for Consulting	\$5,000-9,999
CRV_00009291	Greg Jones	Faculty and Co-investigator	Proposal to Create IPEnclave, a Machine Intelligence-based system for Innovative Organizations to Assess, Manage and License Intellectual Property	University Innovation Services, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00009477	Howard Colman	Associate Professor and Co-Investigator	A Phase 1b/2 Study of Repeat rAdiation, Minocycline, and Bevacizumab in patients with recurrent gliOma (RAMBO)	Hoffman La Roche/Genetech	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00009676	Kathryn Peterson	Associate Professor (Clinical) and Co-Investigator	Radioimaging Eosinophilia	Immviz	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00009961	Greg Jones	Faculty and Co-investigator	Automated Dynamic Lists for Efficient Electronic Health Record Management	Clinacuity	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00010313	Meghan Zorn	Physician Assistant and Co-Investigator	PRIDE-HD: A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients w	Teva	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00010340	David Turok	Assistant Professor and Principal Investigator	Patient discomfort with a novel suction based cervical retractor compared to the traditional cervical tenaculum	Bioceptive Inc.	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00010652	Anne Blaschke	Associate Professor and Principal Investigator	ITI Subaward Meningitis SBIR	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00010719	David Turok	Assistant Professor and Principal Investigator	Patient discomfort with a novel suction based cervical retractor compared to the traditional cervical tenaculum	Bioceptive Inc.	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00010929	Dan Kadrmas	Professor and Principal Investigator	Multi-Tracer PET Tumor Imaging	MultiFunctional Imaging, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00010936	Edward Di Bella	Professor and Co-Investigator	Multi-Tracer PET Tumor Imaging	N/A	Intellectual Property	\$10,000-19,999
CRV_00010944	Christopher Pelt	Associate Professor and Co-Investigator	Vanguard SSK 360 Revision Knee System Global Data Collection	Biomet	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00011371	Peter Stevens	Professor and Principal Investigator	Limb Deformity Registry	N/A	Royalty Income from Intellectual Property	>\$100,000
CRV_00011843	Sunil Sharma	Professor and Co-Investigator	(PQB-2) "Driver" vs. "passenger" epigenetic events in Ewing sarcome	Salarius Pharmaceuticals	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00012309	Christopher Peters	Associate Professor and Co-Investigator	Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b	Biomet	Income for Consulting	\$20,000-39,999
CRV_00012310	Christopher Pelt	Associate Professor and Co-Investigator	Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System: GK9b	Biomet	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00012320	Kenneth Aston	Assistant Professor and Co-Investigator	Epigenetics of the Paternal Contribution to Pediatric Cancer Risk	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00012418	James Hotaling	Assistant Professor and Co-Investigator	Preliminary investigation of erectile function using a non-invasive measurement device	Andro360	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00012759	John Fang	Professor (Clinical) and Co-Investigator	Placement of Veritract Smart Feeding Tube: Healthy Human Volunteer Study	Veritract	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00012809	Dan Kadrmas	Professor and Co-Investigator	Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine-plus-Abraxane in Pancreatic Cancer Patients	MultiFunctional Imaging, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00012918	Gerald Krueger	Professor and Principal Investigator	Immune Tolerance Network	Janssen Pharmaceutical Inc	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00012999	Anne Blaschke	Associate Professor and Co-Investigator	Mortality and Morbidity Associated with Respiratory Viral Infection in Infants following Congenital Heart Disease Surgical Repair	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013186	Sunil Sharma	Professor and Principal Investigator	LSD2 Inhibitors	Beta Cat Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013187	Sunil Sharma	Professor and Principal Investigator	Protein targets of Histone-lysine N-methyltransferase Enhancer of zeste homolog 2 (EZH2) related targets	Beta Cat Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013188	Sunil Sharma	Professor and Principal Investigator	Protein targets of Gli, a protein originally isolated in human glioblastoma and an effector of Hedgehog (Hh) signaling (GLI) related targets	Beta Cat Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013409	Luke Simon	Post Doctoral Fellow and Co-Investigator	Micro-Electrophoresis: A novel approach to select mature and genetically fit sperm	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013410	Douglas Carrell	Professor and Principal Investigator	Micro-Electrophoresis: A novel approach to select mature and genetically fit sperm	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013504	Prashant Tathireddy	Research Associate Professor and Co-Investigator	Plasma-assisted atomic layer deposition of alumina and Parylene-C bi-layer encapsulation	Blackrock Microsystems	Employment	\$20,000-39,999
CRV_00013505	Florian Solzbacher	Professor and Principal Investigator	Plasma-assisted atomic layer deposition of alumina and Parylene-C bi-layer encapsulation	Blackrock Microsystems	Income for Consulting	>\$100,000
CRV_00013505	Florian Solzbacher	Professor and Principal Investigator	Plasma-assisted atomic layer deposition of alumina and Parylene-C bi-layer encapsulation	Blackrock Microsystems	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013517	Loren Rieth	Faculty and Co-investigator	Plasma-assisted atomic layer deposition of alumina and Parylene-C bi-layer encapsulation	Blackrock Microsystems	Employment	\$20,000-39,999
CRV_00013808	ALAN MORRIS	Professor and Co-Investigator	Cardiac Image Analysis for Atrial Fibrillation	Marrek, Inc	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013929	Michael Kay	Professor and Principal Investigator	D-PEPTIDE INHIBITORS OF HIV-1 ENTRY	Navigen	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013955	Anne Blaschke	Associate Professor and Co-Investigator	Molecular Classification of Pediatric Cancer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013956	Anne Blaschke	Associate Professor and Co-Investigator	PARAPNEUMONIC EMPYEMA: USE OF MOLECULAR METHODS TO IDENTIFY PATHOGENS AND OUTCOME	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00013963	Anne Blaschke	Associate Professor and Co-Investigator	Molecular Evaluation of Pediatric Joint Fluid	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00014023	Gerald Krueger	Professor and Co-Investigator	Vascular Inflammation in Psoriasis Extension (VIP-E) Trial	Abbott Pharmaceutical	Income for Consulting/Education/Sp eaking	\$20,000-39,999
CRV_00014102	Dana Carroll	Distinguished Professor and Principal Investigator	Optimizing Genome Engineering with Targetable Nucleases	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00014212	Debra Eckert	Research Associate Professor and Co-Investigator	D-PEPTIDE INHIBITORS OF HIV-1 ENTRY	Navigen	Income for Consulting	\$10,000-19,999
CRV_00014212	Debra Eckert	Research Associate Professor and Co-Investigator	D-PEPTIDE INHIBITORS OF HIV-1 ENTRY	Navigen	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00014290	Agnes Ostafin	Research Associate Professor and Principal Investigator	Haptoglobin Treatment to Reduce Complication of Sickle Cell Disease	Nanoshell Company, LLC	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00014486	Christopher Peters	Associate Professor and Principal Investigator	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	Biomet	Income for Consulting/Education/Sp eaking	\$20,000-39,999
CRV_00014487	Christopher Pelt	Associate Professor and Principal Investigator	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	Biomet	Income for Consulting/Education/Sp eaking	\$20,000-39,999
CRV_00014527	cheryl wright	Associate Professor and Principal Investigator	SketchUp Workshop Program Evaluation	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00014528	Scott Wright	Associate Professor and Co-Investigator	SketchUp Workshop Program Evaluation	NeuroVersity	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00014697	James Hotaling	Associate Professor and Principal Investigator	StreamDx	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00014779	Stephane Meystre	Assistant Professor and Principal Investigator	Automated Dynamic Lists for Efficient Electronic Health Record Management	Clinacuity	CEO/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00015271	David Shprecher	Adjunct Associate Professor and Principal Investigator	A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine	Teva Neuroscience	Income for Consulting	\$10,000-19,999
CRV_00015611	Gerald Krueger	Professor and Co-Investigator	Vascular Inflammation in Psoriasis Trial (VIP) Protocol #814278 (A Trial to Determine the Effect of Psoriasis Treatment on Cardiometabolic Disease)	Abbvie	Income for Consulting/Education/Sp eaking/Expert Witness	\$40,000-59,999
CRV_00015946	Jiyuan Yang	Research Professor and Co-investigator	Backbone Degradable Polymer-Drug Conjugates for the Treatment of Ovarian Cancer	TheraTarget	Employment	\$20,000-39,999
CRV_00015946	Jiyuan Yang	Research Professor and Co-investigator	Backbone Degradable Polymer-Drug Conjugates for the Treatment of Ovarian Cancer	TheraTarget	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00015955	Michael Deininger	Professor and Principal Investigator	OHSU IIT Incyte 10262>>Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CS3FR	Incyte	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00015969	Dan Kadrmas	Professor and Principal Investigator	Multi-Tracer PET/CT Imaging of Gemcitabine Response in Pancreatic Cancer	MultiFunctional Imaging, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00016089	Flory Nkoy	Research Assistant Professor and Principal Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00016090	Bernhard Fassl	Assistant Professor (Clinical) and Co-Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00016091	Bryan Stone	Professor (Clinical) and Co-Investigator	Organizational Factors Associated with Improved Inpatient Pediatric Asthma Care	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00016121	Matthew Converse	Graduate Assistant and Co-Investigator	Validation study of urine flow rate monitoring with novel device: StreamDx.	Stream Dx	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00016689	John Fang	(Clinical) Professor and Co-Investigator	Placement of Veritract Smart Feeding Tube: Healthy Human Volunteer Study	Veritract	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00017107	James Martin	Associate Professor and Principal Investigator	Active Desk: A Novel Invention for Improving Health in the Workplace	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00017534	David Turok	Associate Professor (Clinical) and Principal Investigator	(TRIBE) Tracking IUD Bleeding Experiences: An evaluation of bleeding profiles in new intrauterine device users	Teva Women's Health	Employment/Advisory Board	\$5,000-9,999
CRV_00017632	Philipp Taussky	Associate Professor and Principal Investigator	Prospective Study on Embolization of Intracranial Aneurysms with Pipeline Embolization Device (PREMIER)	Covidien	Income for Consulting	\$40,000-59,999
CRV_00017693	Howard Colman	Professor and Co-Investigator	BTT12-01: A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab	Hoffman La Roche/Genetech	Income for Consulting	\$5,000-9,999
CRV_00017695	Howard Colman	Professor and Principal Investigator	BTT12-01>> A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab	Hoffman La Roche/Genetech	Income for Consulting	\$5,000-9,999
CRV_00017740	Roger Freedman	Professor (Clinical) and Principal Investigator	Adapt Response Clinical Study	Medtronic	Income for Consulting/Safety Monitory Committee	\$5,000-9,999
CRV_00018036	Roger Freedman	Professor (Clinical) and Principal Investigator	AdaptResponse	Medtronic	Income for Consulting/Safety Monitory Committee	\$5,000-9,999
CRV_00018275	John Kircher	Professor and Principal Investigator	Validation of the Ocular-motor Deception Test for Identifying Drug Use Violations	Converus	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00018821	Raminder Nirula	Professor and Principal Investigator	Patient Driven Surgical Discharge Process Improvement	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00019133	Gerald Krueger	Professor and Co-Investigator	A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics	Janssen Pharmaceutical Inc	Income for Consulting/Education/Sp eaking	\$20,000-39,999

CRV_00019381	David Turok	Associate Professor (Clinical) and Principal Investigator	An Evaluation of Bleeding Profiles in New Users of the Copper T380 IUD	Teva Women's Health	Employment/Advisory Board	\$5,000-9,999
CRV_00019665	Dan Woltz	Professor and Co-Investigator	Validation of the Ocular-motor Deception Test for Identifying Drug Use Violations	Converus	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00020335	David Turok	Associate Professor (Clinical) and Principal Investigator	The Copper T380A IUD vs. Oral Levonorgestrel for Emergency Contraception	Teva Women's Health	Employment/Advisory Board	\$5,000-9,999
CRV_00021028	Carl Wittwer	Professor and Co-Investigator	Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics	N/A	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00021164	Anne Blaschke	Associate Professor and Principal Investigator	Procalcitonin in Pediatric Pneumonia	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00021190	Carol Bruggers	Professor and Principal Investigator	Prototype video game of incentive-based physical exercise for adolescent cancer patients (PE GAME): directly coupling physical exercise, via visualization and active participation, to an empowerment of fighting cancer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00021268	Howard Colman	Professor and Principal Investigator	DF/HCC 14-477>>Phase II Study of Pembrolizumab (MK-3475) With and Without Bevacizumab for Recurrent Glioblastoma	Hoffman La Roche/Genetech	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00021288	Anne Cook	Professor and Co-Investigator	Validation of the Ocular-motor Deception Test for Identifying Drug Use Violations	Converus	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00021451	Sunil Sharma	Professor and Principal Investigator	Preclinical Development of HCI-2577 for Ewing's Sarcoma	Saliarius Pharmaceuticals	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00021570	Peter Stevens	Professor and Principal Investigator	Correction of angular deformities due to focal fibrocartilaginous dysplasia using guided growth.	Orthopediatrics, Inc.	Royalty Income from Intellectual Property	>\$100,000
CRV_00021570	Peter Stevens	Professor and Principal Investigator	Correction of angular deformities due to focal fibrocartilaginous dysplasia using guided growth.	Orthopediatrics, Inc.	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00021750	Paul Bernstein	Professor and Principal Investigator	Macular Pigment Measurements in Eye & Other Tissues	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00022076	Jayant Agarwal	Associate Professor and Co-Investigator	Pre-Screening and Screening to identify the VA (and/or military) population that meets medical criteria for advanced prosthetic devices	DJO Surgical	Income for Consulting	\$10,000-19,999
CRV_00022076	Jayant Agarwal	Associate Professor and Co-Investigator	Pre-Screening and Screening to identify the VA (and/or military) population that meets medical criteria for advanced prosthetic devices	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00022085	James Beck	Adjunct Assistant Professor and Co-Investigator	Pre-Screening and Screening to identify the VA (and/or military) population that meets medical criteria for advanced prosthetic devices	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00022401	Anne Blaschke	Associate Professor and Principal Investigator	FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00022451	James Barrett	Assistant Professor (Clinical) and Co-Investigator	Patient Driven Surgical Discharge Process Improvement	ProMD	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00022546	Greg Jones	Faculty and Co-investigator	Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing	Clinacuity	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00022632	Philipp Taussky	Associate Professor and Co-Investigator	Outcomes of Pipeline Embolization Device for Intracranial Aneurysms	Covidien	Income for Consulting	\$60,000-79,999
CRV_00022643	Philipp Taussky	Associate Professor and Principal Investigator	PROSPECTIVE STUDY ON EMBOLIZATION OF INTRACRANIAL ANEURYSMS WITH PIPELINE EMBOLIZATION DEVICE	Covidien	Income for Consulting	\$60,000-79,999
CRV_00023217	Michael Kay	Professor and Principal Investigator	Protease-Resistant D-peptide Inhibitors of Ebola Entry	Navigen	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00023414	Michael Deininger	Professor and Principal Investigator	Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study)	Novartis	Income for Consulting	\$10,000-19,999
CRV_00023414	Michael Deininger	Professor and Principal Investigator	Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study)	Pfizer	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00023414	Michael Deininger	Professor and Principal Investigator	Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study)	Bristol-Myers Squibb	Income for Consulting	\$5,000-9,999

CRV_00023748	Michael Kay	Professor and Principal Investigator	Highly specific anti-toxin therapies for severe bacterial gut infections	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00023765	cheryl wright	Associate Professor and Co-Investigator	The Evaluation of a Peer-Teaching Technology Education Program for Youth on the Autism Spectrum	NeuroVerity	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00023918	Gerald Krueger	Professor and Co-Investigator	A PHASE 4, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY OF APREMILAST (CC-10004), IN SUBJECTS WITH MODERATE PLAQUE PSORIASIS	Celgene	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00024175	David Turok	Associate Professor (Clinical) and Principal Investigator	RAPID EC – RCT Assessing Pregnancy with Intrauterine Devices for Emergency Contraception	Teva Women's Health	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00024243	Michael Deininger	Professor and Principal Investigator	Avillion AV001>>A Multicenter Phase 3, Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Novartis	Income for Consulting	\$10,000-19,999
CRV_00024243	Michael Deininger	Professor and Principal Investigator	Avillion AV001>>A Multicenter Phase 3, Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Pfizer	Income for Consulting	\$5,000-9,999
CRV_00024284	David Turok	Associate Professor (Clinical) and Faculty Sponsor	Intent to receive a post-partum contraceptive implant or IUD, continuation rates, and patient satisfaction	Teva Women's Health	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00024422	Michael Kay	Professor and Principal Investigator	RAPID: Optimizing experimental approaches to Ebola membrane fusion inhibitor peptide design through high-throughput biomolecular simulation workflows on Blue Waters	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00024913	Jayant Agarwal	Associate Professor and Co-Investigator	Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment	DJO Surgical	Income for Consulting	\$10,000-19,999
CRV_00024913	Jayant Agarwal	Associate Professor and Co-Investigator	Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment	DJO Surgical	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00024914	James Beck	Adjunct Assistant Professor and Co-Investigator	Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00025171	David Turok	Associate Professor (Clinical) and Principal Investigator	Highly Effective Reversible Contraceptive Initiative—Salt Lake (HER-SLC)	Teva Women's Health	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00025488	James Beck	Adjunct Associate Professor and Principal Investigator	Microbiome and Innate Immunity with Percutaneous Osseointegrated Prostheses	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00025489	Jayant Agarwal	Associate Professor and Co-Investigator	Microbiome and Innate Immunity with Percutaneous Osseointegrated Prostheses	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00025491	Sujeevini Jeyapalina	Adjunct Assistant Professor and Co-Investigator	Microbiome and Innate Immunity with Percutaneous Osseointegrated Prostheses	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00026093	Allison Payne	Research Associate Professor and Principal Investigator	Safety and Efficacy of Magnetic Resonance Guided High Intensity Focused Ultrasound Ablation of Renal Sympathetic Arteries	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00026206	jiyuan Yang	Research Professor and Co-investigator	Drug-Free Macromolecular Therapeutics	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00026207	Paul Shami	Professor and Co-Investigator	Drug-Free Macromolecular Therapeutics	Bastion Biologics	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00026247	Jindrich Kopecek	Distinguished Professor and Principal Investigator	Drug-Free Macromolecular Therapeutics	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00027452	Luke Simon	Post Doctoral Fellow and Co-Investigator	A comparative analysis of sperm preparation methods to isolate genetically fit sperm	N/A	Intellectual Property	\$20,000-39,999
CRV_00027721	Tibor Kovacsovics	Professor (Clinical) and Principal Investigator	Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma	Celgene	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00028441	Howard Colman	Professor and Co-Investigator	NRG/ECOG/ACRIN/NCI EAY131 (CIRB) >> Molecular Analysis for Therapy Choice (MATCH)	Hoffman La Roche/Genetech	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00030218	Carl Wittwer	Professor and Co-Investigator	Development of a rapid genetic test for positive sample identification.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00030577	Carl Wittwer	Professor and Co-Investigator	Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00030686	Anne Blaschke	Associate Professor and Co-Investigator	Evaluation of Estimated Patient Outcomes with access to Rapid Molecular-Based Diagnostic Testing for Meningitis/Encephalitis -- BioFire Study # DX-SDY-022668	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00030958	Tibor Kovacovics	Professor (Clinical) and Principal Investigator	Alliance/ECOG-ACRIN E1910 (CIRB)>>A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults	Amgen	Income for Consulting	\$10,000-19,999
CRV_00031094	Howard Colman	Professor and Co-Investigator	ALLIANCE A071401>> Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations	Hoffman La Roche/Genetech	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00032369	Luming Zhou	Research Associate and Co-Investigator	Development of a rapid genetic test for positive sample identification.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00032392	Roger Freedman	Professor (Clinical) and Principal Investigator	Collection of ElectroMagnetic Interference Signals Induced by an Electrosurgery Device in Patients with ICDs or CRT-Ds	Medtronic	Income for Consulting/Safety Monitory Committee	\$5,000-9,999
CRV_00032407	Peter Stevens	Professor and Principal Investigator	A Comparison of Two Surgical Methods of Management for Perthes Disease	Orthofix, Inc	Income for Consulting	\$10,000-19,999
CRV_00032407	Peter Stevens	Professor and Principal Investigator	A Comparison of Two Surgical Methods of Management for Perthes Disease	Orthofix, Inc	Royalty Income from Intellectual Property	\$60,000-79,999
CRV_00033059	Loren Rieth	Faculty and Co-investigator	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device?	Blackrock Microsystems	Employment	\$20,000-39,999
CRV_00033175	Sujeevini Jeyapalina	Adjunct Associate Professor and Principal Investigator	Microbiome and Innate Immunity with Percutaneous Osseointegrated Prostheses	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00033186	Ken Johnson	Professor and Co-Investigator	Evaluation of Information Displays- A Paper, Computer and Simulator Based Study	Applied Medical Visualizations	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00033188	Noah Syroid	Research Associate and Principal Investigator	Evaluation of Information Displays- A Paper, Computer and Simulator Based Study	Applied Medical Visualizations	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00033347	Manoranjan Misra	Professor and Principal Investigator	TB Sensor Assessment	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00033348	Swomitra Mohanty	Assistant Professor and Co-Investigator	TB Sensor Assessment	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00033371	Djordje Atanackovic	Associate Professor and Co-Investigator	Hemostatic Effects of VELCADE** Treatment in Multiple Myeloma Patients	Millennium Pharmaceuticals	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00034215	Anne Blaschke	Associate Professor and Co-Investigator	Evaluation of Estimated Patient Outcomes with access to Rapid Molecular-Based Diagnostic Testing for Meningitis/Encephalitis	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00034322	Sunil Sharma	Adjunct Professor and Principal Investigator	(PQB-2) âDriverâ vs. âpassengerâ epigenetic events in Ewing sarcoma	N/A	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00034367	Joel Cooper	Faculty and Principal Investigator	Measuring Cognitive Distraction on the Road	Red Scientific	Employment	\$5,000-9,999
CRV_00035192	Ravi Ranjan	Associate Professor and Co-Investigator	Quadrupolar Pacing Post Approval Study (QUAD PAS)	St. Jude Medical	Income for Consulting	\$10,000-19,999
CRV_00035298	Philipp Taussky	Associate Professor and Co-Investigator	StrokeNet cIRB Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE 3)	Covidien	Income for Consulting	\$60,000-79,999
CRV_00035730	Swomitra Mohanty	Assistant Professor and Principal Investigator	TB Breathalyzer	Nanosynth Materials and Sensors Inc	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00036664	Anne Blaschke	Associate Professor and Co-Investigator	FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00036825	Douglas Adler	Professor and Principal Investigator	Clinical feasibility and efficacy of a new digital single-operator peroral cholangiopancreatocopy system: a multicenter registry	Boston Scientific	Income for Consulting	\$10,000-19,999
CRV_00036990	Swomitra Mohanty	Associate Professor and Principal Investigator	Non-invasive TB Triage and Patient Mapping Platform Using Breath via Low-Cost Titanium Dioxide Nanotube Sensor	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00036993	Luming Zhou	Research Associate and Co-Investigator	Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00037314	Ken Johnson	Professor and Co-Investigator	Comparison of Effect Site Concentrations of Anesthetic Agents with Processed Electroencephalography	Medical Visualizations	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00037433	Bryan Stone	Professor (Clinical) and Principal Investigator	Transient Receptor Potential (TRP) Ion Channel Gain of Function Polymorphisms in Pollution Associated Asthma Exacerbations	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00038433	Gerald Krueger	Professor and Co-Investigator	VIP-S - CAIN457AUS02 - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the effect of secukinumab on aortic vascular inflammation and cardiometabolic biomarkers after 12 weeks of treatment, compared to placebo	Novartis	Income for Consulting/Education/Spreading	\$20,000-39,999
CRV_00038962	Gerald Krueger	Professor and Co-Investigator	I1F-MC-RHBQ - A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients with Moderate-to-Severe Genital Psoriasis	Eli Lilly and Co.	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00039373	Anne Blaschke	Associate Professor and Co-Investigator	Sepsis Direct grant	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00039543	Bradley Katz	Professor and Principal Investigator	Spectacle Tints and Thin-Films to Reduce Headache Frequency in Patients with Chronic Migraine	Axon Optics, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00039544	Steve Blair	Professor and Co-Investigator	Spectacle Tints and Thin-Films to Reduce Headache Frequency in Patients with Chronic Migraine	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00039545	Kathleen Digre	Professor and Co-Investigator	Spectacle Tints and Thin-Films to Reduce Headache Frequency in Patients with Chronic Migraine	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00039818	Carl Wittwer	Professor and Co-Investigator	Collection of anonymized whole-blood samples from BioFire employees for use in the development, verification, and validation of the Infectious Diseases (ID) Fever Panel.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00039984	Peter Stevens	Professor and Principal Investigator	Cozen phenomenon-resolved with guided growth	N/A	Royalty Income from Intellectual Property	\$60,000-79,999
CRV_00040027	CAMERON METCALF	Associate Director and Principal Investigator	Developing a Peripherally-Acting Peptidic Galanin Analog for Treatment of Postoperative Pain	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00040402	Zachary Imel	Assistant Professor and Principal Investigator	Implementation of Technology-Based Evaluation of Motivational Interviewing	Behavioral Informatics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00040664	Greg Jones	Faculty and Co-investigator	Clinical Text Automatic De-Identification to Support Large Scale Data Reuse and Sharing	Clinacuity	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00040743	Frederick Welt	Professor (Clinical) and Co-investigator	Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System in Patients at Low Risk for Surgical Aortic Valve Replacement.	Medtronic	Income for Consulting	\$10,000-19,999
CRV_00040820	Andy Peiffer	Research Assistant Professor and Co-investigator	Wolf-Hirschhorn Genotype Correlation Project	Lineagen	Income for Consulting	\$40,000-59,999
CRV_00040825	Jeremy Gilliland	Assistant Professor and Principal Investigator	Fluoroscopic Grid use in Total Hip Arthroplasty	OrthoGrid Technologies	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00041018	Tibor Kovacsovics	Professor (Clinical) and Principal Investigator	Onyx CFZ013 >> Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma	Celgene	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00041427	Karen Ho	Adjunct Associate Professor and Principal Investigator	Wolf-Hirschhorn Genotype Correlation Project	Lineagen	Employment	\$10,000-19,999
CRV_00041828	Christopher Peters	Professor and Co-Investigator	Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G7 Dual Mobility Construct	Biomet	Income for Consulting	\$20,000-39,999
CRV_00041829	Christopher Pelt	Associate Professor and Co-Investigator	Evaluation of serum metal ion levels in a series of patients undergoing primary or revision total hip arthroplasty with the G7 Dual Mobility Construct	Biomet	Income for Consulting	\$20,000-39,999
CRV_00041987	cheryl wright	Associate Professor and Co-Investigator	FLOCK: A software-development collaboration between Modern Dance, FCS (Autism Research) and the Entertainment Arts and Engineering Program's GApp Lab for Therapeutic Games and Apps	NeuroVersity	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00042378	Glenn Prestwich	Professor and Co-Investigator	Glycosaminoglycan-base Therapy For Chronic Rhinosinusitis	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00042789	David Turok	Associate Professor (Clinical) and Principal Investigator	RCT Assessing Pregnancy with Intrauterine Devices for Emergency Contraception	Teva Women's Health	Income for Consulting/Advisory Board	\$5,000-9,999

CRV_00042908	cheryl wright	Associate Professor and Co-Investigator	Assessing Technology Skills and Employability in Adolescents and Adults with Autism Spectrum Disorder	NeuroVersity	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00043083	Michael Deininger	Professor and Co-Investigator	Novartis CPKC412AUS56X Expanded Access >> An open-label, multicenter, Expanded Treatment Protocol of Midostaurin (PKC412) in adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligib	Novartis	Income for Consulting	\$10,000-19,999
CRV_00043229	Edward Dudek	Professor and Principal Investigator	Biomarkers for epileptogenesis after brain injury	Epitel	Income for Consulting	\$20,000-39,999
CRV_00043229	Edward Dudek	Professor and Principal Investigator	Biomarkers for epileptogenesis after brain injury	Epitel	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00043264	Florian Solzbacher	Professor and Principal Investigator	Pre-Clinical Development of Smart Hydrogels	Sentiomed	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00044022	Mary Scholand	Associate Professor and Principal Investigator	PRM-151 A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Bristol-Myers Squibb	Equity Interest	\$40,000-59,999
CRV_00044597	David Turok	Associate Professor (Clinical) and Princial Investigator	A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated with Emergency Contraception	Teva Women's Health	Income for Consulting	\$5,000-9,999
CRV_00044929	Michael Deininger	Professor and Principal Investigator	Novartis CABL001X2101>>A Phase I, Multicenter, Open-Label Study Of Oral ABL001 In Patients With Chronic Myelogenous Leukemia Or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia	Novartis	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00045056	Michael Kay	Professor and Principal Investigator	Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease	Navigen	Employment	\$10,000-19,999
CRV_00045056	Michael Kay	Professor and Principal Investigator	Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00045147	Debra Eckert	Research Associate Professor and Co-Investigator	Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease	Navigen	Income for Consulting	\$5,000-9,999
CRV_00045147	Debra Eckert	Research Associate Professor and Co-Investigator	Oral/Topical D-peptide TNF Inhibitors for Inflammatory Bowel Disease	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00045186	Christine Abraham	Graduate Research Assistant and Co-Investigator	Changes in gait speed and kinematics after participation in a 2 week intensive mobility program in stroke survivors.	Veristride	Employment	\$60,000-79,999
CRV_00045195	Florian Solzbacher	Professor and Principal Investigator	The Snow Pixel - a micro hotplate snow and precipitation sensor	Blackrock Microsystems	Income for Consulting	>\$100,000
CRV_00045195	Florian Solzbacher	Professor and Principal Investigator	The Snow Pixel - a micro hotplate snow and precipitation sensor	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00045195	Florian Solzbacher	Professor and Principal Investigator	The Snow Pixel - a micro hotplate snow and precipitation sensor	Blackrock Microsystems	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00045269	Djordje Atanackovic	Associate Professor and Principal Investigator	Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy	Millennium Pharmaceuticals	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00045269	Djordje Atanackovic	Associate Professor and Principal Investigator	Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy	Celgene	Income for Consulting	\$10,000-19,999
CRV_00045271	Tibor Kovacovics	Professor (Clinical) and Co-investigator	Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy	Celgene	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00045272	Michael Deininger	Professor and Co-Investigator	Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy	Novartis	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00045558	PING MEN	Research Associate and Principal Investigator	New therapeutics targeting skeletal excessive Fe for thalassemia major bone loss	NanoMedic	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00045640	Thomas Higgins	Professor and Co-Investigator	"What happens on the back table? Viability and Osteogenic Potential of RIA bone graft as a function of time and temperature."	Depuy Sythes	Income for Consulting	\$10,000-19,999
CRV_00046342	Michael YU	Associate Professor and Principal Investigator	Imaging Prostate Cancer Microenvironment by Collagen Hybridization	3Helix	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00046343	Michael YU	Associate Professor and Principal Investigator	Study and Application of Collagen Mimetic Peptide-Collagen Hybridization	3Helix	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00046344	Michael YU	Associate Professor and Principal Investigator	Collagen-Targeted Therapeutics of Cathepsin Inhibitors	3Helix	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00046545	Mary Scholand	Associate Professor and Principal Investigator	A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects with Idiopathic Pulmonary Fibrosis (IPF)	Bristol-Myers Squibb	Equity Interest	\$40,000-59,999
CRV_00046750	Jayant Agarwal	Associate Professor and Co-Investigator	TCIP Vessel Coupling	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00046781	Djordje Atanackovic	Associate Professor and Co-Investigator	NRG/ECOG/ACRIN/NCI EAY131-X (CIRB)>> MATCH Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations	Bristol-Myers Squibb	Income for Consulting	\$5,000-9,999
CRV_00046782	Djordje Atanackovic	Associate Professor and Co-Investigator	NRG/ECOG/ACRIN/NCI EAY131-Z1D (CIRB)>>Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)	Bristol-Myers Squibb	Income for Consulting	\$5,000-9,999
CRV_00046950	Jeremiah Alt	Assistant Professor and Principal Investigator	A Novel Glycosaminoglycan-Based Therapeutic for Chronic Rhinosinusitis	Glycomira Therapeutics	Equity Interest	\$10,000-19,999
CRV_00047142	Swomitra Mohanty	Assistant Professor and Principal Investigator	Rapid Monitoring and Assessment of Tuberculosis Treatment at the Point of Care Using Breath	Nanosynth Materials and Sensors Inc	Fees for Research	\$5,000-9,999
CRV_00047142	Swomitra Mohanty	Assistant Professor and Principal Investigator	Rapid Monitoring and Assessment of Tuberculosis Treatment at the Point of Care Using Breath	Nanosynth Materials and Sensors Inc	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00047160	Carl Wittwer	Professor and Co-Investigator	Pilot Clinical Evaluation of the FilmArray® Fever Panel	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00047508	Bruce Gale	Professor and Principal Investigator	Microfluidic Devices for Early (less than 48 hpf), Non-destructive Zebrafish Genotyping	NanoNC	Equity Interest	\$40,000-59,999
CRV_00047508	Bruce Gale	Professor and Principal Investigator	Microfluidic Devices for Early (less than 48 hpf), Non-destructive Zebrafish Genotyping	NanoNC	Employment	\$5,000-9,999
CRV_00047513	Raheel Samuel	Post Doctoral Fellow and Co-Investigator	Microfluidic Devices for Early (less than 48 hpf), Non-destructive Zebrafish Genotyping	NanoNC	Employment	\$20,000-39,999
CRV_00047513	Raheel Samuel	Post Doctoral Fellow and Co-Investigator	Microfluidic Devices for Early (less than 48 hpf), Non-destructive Zebrafish Genotyping	NanoNC	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00047531	Edward Dudek	Professor and Principal Investigator	A rat electrographic model of organophosphate-induced seizures to evaluate delayed treatment with novel anticonvulsants	Rugen	Income for Consulting	\$5,000-9,999
CRV_00047962	Himanshu Sant	Research Assistant Professor and Principal Investigator	Continuous exosome and oncosome separations using a modified SPLITT system	Espira Inc	Employment	\$10,000-19,999
CRV_00047963	Himanshu Sant	Research Assistant Professor and Principal Investigator	A Biodegradable Vascular Coupling Device for End-to-End Anastomosis	Microsurgical Innovations	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00048047	Gerald Krueger	Professor and Co-Investigator	CAIN457A2326 - Clarity - A 52-week, multicenter, randomized, double-blind study of secukinumab (300 mg) to demonstrate efficacy as assessed by Psoriasis Area and Severity Index and Investigator's Global Assessment after 12 weeks of treatment, compared to	Novartis	Income for Consulting/Education/Sp eaking	\$20,000-39,999
CRV_00048055	Tibor Kovacsics	Professor (Clinical) and Co-investigator	Roche Genentech GO29695>>A Phase Ib Study Of The Safety And Pharmacokinetics Of Atezolizumab (Anti Pd L1 Antibody) Alone Or In Combination With An Immomodulatory Drug and/or Daratumumab In Patients With Multiple Myeloma (Relapsed/Refractory And Post Au	Celgene	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00048208	Edward Dudek	Professor and Principal Investigator	Use of organophosphate-induced electrographic seizures in rat pups for screening anticonvulsant drugs for the pediatric population.	Rugen	Income for Consulting	\$5,000-9,999
CRV_00048211	Edward Dudek	Professor and Principal Investigator	A model of organophosphate-induced electrographic seizures in rat to evaluate delayed treatment with novel anticonvulsants	Rugen	Income for Consulting	\$5,000-9,999
CRV_00048250	Michael Riley	Graduate Research Assistant and Co-Investigator	Socioeconomic Status and Learning Transfer in Outdoor Education	NOLS	Employment	\$5,000-9,999
CRV_00048288	Jennifer Heemstra	Associate Professor and Co-Investigator	Mining Complex Human Fluids for New Potential Protein Biomarkers	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00048355	Loren Rieth	Faculty and Co-investigator	Development of an integrated array for simultaneous optical stimulation and electrical recording for the study of cortical circuit function in the nonhuman primate brain	Blackrock Microsystems	Employment	\$20,000-39,999
CRV_00048556	Michael Deininger	Professor and Principal Investigator	A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses	Ariad	Income for Consulting	\$5,000-9,999

CRV_00048724	Neal Patwari	Assistant Professor and Principal Investigator	PlusOne: Prototyping and Validation of a Wireless In Home Breathing Monitor for Prevention of Overdose Deaths	Xandem Technology	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00048742	Neal Patwari	Assistant Professor and Principal Investigator	Radio-Based Respiration Monitoring During Sleep	Xandem Technology	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00048955	Mark Yandell	Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES	Omnia	Income for Consulting/Advisory Board	\$20,000-39,999
CRV_00048955	Mark Yandell	Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES	Omnia	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00048955	Mark Yandell	Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES	IDbyDNA	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049005	Michael Deininger	Professor and Co-Investigator	THERAPEUTIC DRUG MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY USING SCALP HAIR CONCENTRATIONS	Novartis	Income for Consulting	\$10,000-19,999
CRV_00049005	Michael Deininger	Professor and Co-Investigator	THERAPEUTIC DRUG MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY USING SCALP HAIR CONCENTRATIONS	Ariad	Income for Consulting	\$5,000-9,999
CRV_00049006	Tibor Kovacs	Professor (Clinical) and Principal Investigator	AbbVie M15-538>> A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma	Amgen	Income for Consulting/Education/Speaking	\$10,000-19,999
CRV_00049098	Bradley Katz	Professor and Principal Investigator	Spectacle Tints and Thin-Films to reduce headache frequency in patients with chronic migraine	Axon Optics, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049422	Michael Deininger	Professor and Principal Investigator	Ariad AP24534-14-203>>A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses	Ariad	Income for Consulting	\$5,000-9,999
CRV_00049463	Gabor Marth	Professor and Co-Investigator	Utah Genome Project	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049485	Gerald Krueger	Professor and Principal Investigator	Psoriasis Research Fellowship	Abbvie	Income for Consulting/Education/Speaking/Expert Witness	\$10,000-19,999
CRV_00049533	cheryl wright	Associate Professor and Co-Investigator	Focus group evaluation of a prototype app for young adults with autism	NeuroVersity	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049572	Gregory Clark	Associate Professor and Principal Investigator	Embodied Neuroprostheses	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049573	Gregory Clark	Associate Professor and Co-Investigator	Sensory-Motor Integration via Recording and Stimulating Arm Nerves	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049575	Gregory Clark	Associate Professor and Co-Investigator	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device?	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00049705	David Turok	Associate Professor (Clinical) and Principal Investigator	Clinical Evaluation of Long-Acting Reversible Contraceptives	Teva Women's Health	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00050130	Michael Deininger	Professor and Principal Investigator	Stopping Tyrosine Kinase Inhibitors in CML Patients	Novartis	Income for Consulting	\$10,000-19,999
CRV_00050138	Swomitra Mohanty	Assistant Professor and Principal Investigator	Development of Incubator with VOC Sensor for Rapid Culture Assessment	Nanosynth Materials and Sensors Inc	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00050145	Michael Kay	Professor and Principal Investigator	Preclinical development of a potent D-peptide RSV inhibitor	Navigen	Employment	\$10,000-19,999
CRV_00050145	Michael Kay	Professor and Principal Investigator	Preclinical development of a potent D-peptide RSV inhibitor	Navigen	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00050203	Frederick Welt	Professor (Clinical) and Co-investigator	Evolut R Low Risk Study	Medtronic	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00050220	Glenn Prestwich	Professor and Principal Investigator	MECHANISMS OF HYALURONAN SIGNALING AND TURNOVER IN PROSTATE CANCER	Glycomira Therapeutics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00050448	Stavros Drakos	Associate Professor and Co-Investigator	A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction	Novartis	Income for Consulting	\$5,000-9,999
CRV_00050594	Mark Yandell	Professor and Co-Investigator	Metagenomic approach to the evaluation of myocarditis	IDbyDNA	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00050595	Robert Schlaberg	Assistant Professor and Co-Investigator	Metagenomic approach to the evaluation of myocarditis	IDbyDNA	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00050601	Troy Andersen	Associate Professor (Lecturer) and Principal Investigator	Memory Care Partner	PAMS, Inc.	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00050813	Jindrich Kopecek	Distinguished Professor and Principal Investigator	Initiation of Apoptosis in Rituximab-Resistant Cell Lines Mediated by Drug-Free Therapeutics	Bastion Biologics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00050890	Stavros Drakos	Associate Professor and Co-Investigator	Entresto (LCZ696) In Advanced Heart Failure (LIFE Study)	Novartis	Income for Consulting	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00051049	Jennifer Heemstra	Associate Professor and Principal Investigator	A New Sample Preparation Method to Delve Deeper into the Proteome	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00051269	Russell Butterfield	Assistant Professor and Principal Investigator	An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051271	Russell Butterfield	Assistant Professor and Principal Investigator	Expanded Access Program (EAP) to provide Nusinersen to Patients with Infantile-onset Spinal Muscular Atrophy (SMA)	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051272	Russell Butterfield	Assistant Professor and Principal Investigator	An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051276	Russell Butterfield	Assistant Professor and Principal Investigator	Expanded Access Program (EAP) to provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051281	Russell Butterfield	Assistant Professor and Co-Investigator	Health Endpoints and Longitudinal Progression in Myotonic Dystrophy type 1(HELP-DM)	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051290	Russell Butterfield	Assistant Professor and Co-Investigator	Health Endpoints and Longitudinal Progression in Congenital Myotonic Dystrophy (HELP-CDM)	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051402	Jutta Deininger	Nurse Practitioner and Co-Investigator	Novartis CLEE011xUS29 TRINITI-1>> A Phase I/II, single arm, open-label study of Ribociclib in Combination with Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women with HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following	Novartis	Income for Consulting	\$10,000-19,999
CRV_00051407	Gabor Marth	Professor and Principal Investigator	Empowering real-time, web-based genomic big data analysis at commercial scale	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00051408	Russell Butterfield	Assistant Professor and Co-Investigator	An Open-label Extension Study for Patients with Spinal Muscular Atrophy who Previously Participated in Investigational Studies of ISIS 396443	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051409	Russell Butterfield	Assistant Professor and Co-Investigator	A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Muscular Atrophy	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00051410	Russell Butterfield	Assistant Professor and Co-Investigator	An Open-label Study to Assess the Safety and Tolerability of ISIS 396443 in Patients with Spinal Muscular Atrophy who Previously Participated in ISIS 396443-CS2 or ISIS 396443-CS10	Biogen-Idec	Income for Consulting/Advisory Board	\$10,000-19,999

CRV_00051703	Aaron Quinlan	Associate Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES	Base2 Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00051773	Aaron Quinlan	Associate Professor and Co-Investigator	Genetic risk factors in suicide and depression	Base2 Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00051858	Troy Andersen	Associate Professor (Lecturer) and Co-Investigator	EXEMPTION UMBRELLA: Clinical Outcomes and Health Systems in Cognitive Care	PAMS, Inc.	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00052152	Orly Alter	Associate Professor and Principal Investigator	Multi-Tensor Decompositions for Personalized Cancer Diagnostics and Prognostics	Eigengene, Inc.	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00052162	Jeremy Gilliland	Assistant Professor and Principal Investigator	Intraoperative Data Collection for the use of a Novel Digital Fluoroscopic Grid	OrthoGrid Technologies	Equity Interest	\$5,000-9,999
CRV_00052163	Mike Anderson	Research Scientist and Co-Investigator	Intraoperative Data Collection for the use of a Novel Digital Fluoroscopic Grid	OrthoGrid Technologies	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00052349	Tibor Kovacovics	Professor (Clinical) and Principal Investigator	AbbVie Inc. M15-656>> A Randomized, Double-Blind, Placebo Controlled Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Naive Elderly Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy	Celgene	Income for Consulting/Education/Sp speaking	\$10,000-19,999
CRV_00052546	Robert Schlaberg	Assistant Professor and Principal Investigator	Reproducibility of pathogen detection by metagenomics	IDbyDNA	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00052631	Michael Deininger	Professor and Principal Investigator	Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients with Mutation of CSF3R	Incyte	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00052822	Terry Box	Associate Professor (Clinical) and Co-Investigator	G5-US-384-1944: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)	Gilead	Income for Consulting	\$20,000-39,999
CRV_00053450	David Warren	Research Associate Professor and Co-Investigator	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device?	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00053467	David Warren	Research Associate Professor and Co-Investigator	Sensory-Motor Integration via Recording and Stimulating Arm Nerves	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00053469	David Warren	Research Associate Professor and Co-Investigator	Embodied Neuroprostheses	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00053644	Michael Deininger	Professor and Principal Investigator	Incyte INCB54828-203>> A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement	Incyte	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00053817	Irene De Biase	Assistant Professor (Clinical) and Co-Investigator	Identification and Description of LAL-D Patients in an EHR Database	Alexion	Income for Consulting/Education/Sp speaking	\$5,000-9,999
CRV_00054303	Mark Yandell	Professor and Co-Investigator	The Metagenomics of Pediatric Eosinophilic Esophagitis (EoE): A Pan-Microbial Survey and T-Cell Receptor Analysis from Esophageal Tissue	IDbyDNA	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00054305	Robert Schlaberg	Assistant Professor and Co-Investigator	The Metagenomics of Pediatric Eosinophilic Esophagitis (EoE): A Pan-Microbial Survey and T-Cell Receptor Analysis from Esophageal Tissue	IDbyDNA	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00054321	Carl Wittwer	Professor and Co-Investigator	Testing of De-Identified Clinical Specimens for use in Product Development and Clinical Studies for the Fever Panel.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00054324	Carl Wittwer	Professor and Co-Investigator	Collection of anonymized urine samples from BioFire employees for use in the development, verification, and validation of the Infectious Diseases (ID) Fever Panel.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00054464	Joel Cooper	Research Associate Professor and Co-Investigator	Assessment of assistance systems on the road	Red Scientific	Income for Consulting	\$5,000-9,999
CRV_00054464	Joel Cooper	Research Associate Professor and Co-Investigator	Assessment of assistance systems on the road	Red Scientific	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00054509	Carl Wittwer	Professor and Co-Investigator	Clinical Evaluation of the FilmArray® Global Fever (GF) Panel – BioFire Defense Site-Specific Activities	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00054616	Howard Colman	Professor and Co-Investigator	NRG/ECOG/ACRIN/NCI EAY131-J (CIRB)>>MATCH Treatment Subprotocol J: Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification	Hoffman La Roche/Genetech	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00054777	Jutta Deininger	Nurse Practitioner and Co-Investigator	Novartis CLAG525X2101C>>A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies	Novartis	Income for Consulting	\$10,000-19,999
CRV_00054801	Michael Deininger	Professor and Principal Investigator	A phase I, multicenter, open-label study of oral ABL001 in patients with chronic myelogenous leukemia or Philadelphia Chromosome-positive acute lymphoblastic leukemia	Novartis	Income for Consulting	\$10,000-19,999
CRV_00054836	Michael Deininger	Professor and Co-Investigator	Incyte INCB 18424-272 >> A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects with Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea	Incyte	Income for Consulting	\$10,000-19,999
CRV_00054922	Brook Martin	Research Associate Professor and Principal Investigator	Influence of an expanded mandatory bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	Gold Standard Research, LLC	Equity Interest	>\$100,000
CRV_00055132	Aaron Quinlan	Associate Professor and Principal Investigator	Novel DNA damage response gene from genomic screening	Base2 Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00055250	Bryan Jones	Research Associate Professor and Principal Investigator	Retinal Remodeling	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00055376	Paul Bernstein	Professor and Principal Investigator	Biochemistry and Pharmacology of the Macular Carotenoids	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00055511	David Turok	Associate Professor (Clinical) and Principal Investigator	A multi-center, single-blind, randomized clinical trial to compare two copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard	Teva Women's Health	Employment	\$10,000-19,999
CRV_00055523	David Turok	Associate Professor (Clinical) and Principal Investigator	Rates of contraceptive failure when unprotected intercourse has occurred 6-14 days prior to contraceptive initiation	Teva Women's Health	Employment	\$10,000-19,999
CRV_00055929	K-T VARLEY	Assistant Professor and Principal Investigator	A partnership to enable clinical ctDNA testing for breast cancer recurrence	Kailos Genetics	Income for Consulting	\$20,000-39,999
CRV_00055929	K-T VARLEY	Assistant Professor and Principal Investigator	A partnership to enable clinical ctDNA testing for breast cancer recurrence	Kailos Genetics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00056194	Gabor Marth	Professor and Principal Investigator	Integration of iobio genetic analysis tools into ARUP diagnostic pipelines	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00056247	Sheila Crowell	Associate Professor and Principal Investigator	Dialectical behavior therapy skills in schools: Skills training for emotion problem solving for adolescents (DBT STEPS-A)	Utah Center for Evidence Based Treatment	Income for Clinical Services	\$10,000-19,999
CRV_00056247	Sheila Crowell	Associate Professor and Principal Investigator	Dialectical behavior therapy skills in schools: Skills training for emotion problem solving for adolescents (DBT STEPS-A)	Utah Center for Evidence Based Treatment	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00056491	Richard Cawthon	Research Associate Professor and Principal Investigator	Novel Quantitative PCR Assays of Telomeric DNA	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00056856	Sean Runnels	Assistant Professor (Clinical) and Principal Investigator	Airway exchange catheter tip control in the trachea with and without videolaryngoscopy in airway mannequins	Through the cords	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00056924	Richard Cawthon	Research Associate Professor and Principal Investigator	Novel Quantitative PCR Assays of Telomeric DNA	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00057012	Mark Yandell	Professor and Co-Investigator	A scalable, integrative, multi-omic analysis platform	Omnia	Income for Consulting/Advisory Board	\$20,000-39,999
CRV_00057012	Mark Yandell	Professor and Co-Investigator	A scalable, integrative, multi-omic analysis platform	Omnia	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00057167	Paul Bernstein	Professor and Principal Investigator	Spark Therapeutics: Natural History of Individuals with Retinal Degeneration due to Mutations in the CHM Gene	Spark Therapeutics	Income for Consulting/Advisory Board	\$5,000-9,999

CRV_00057481	Eric Schmidt	Professor and Principal Investigator	Symbiosis and Chemical Diversity Generation	Synthetic Biodesign	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00057674	Gerald Krueger	Professor and Co-Investigator	CAIN457AUS07 - ObePso-S - A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore changes in subcutaneous adipose tissue and modulation of skin inflammation after 12 weeks of treatment with secukinumab, compared to pl	Novartis	Income for Consulting/Education/Sp eaking	\$20,000-39,999
CRV_00057719	Charles Atwood	Professor and Principal Investigator	Evidence-based and evidence-generating approaches to understanding STEM learning across the Western States	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00057767	Michael Riley	Graduate Research Assistant and Principal Investigator	Exploring the Developmental Networks of Outdoor Educators	NOLS	Employment	\$5,000-9,999
CRV_00057865	Brook Martin	Research Associate Professor and Principal Investigator	The influence of an expanded bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	Gold Standard Research, LLC	Equity Interest	>\$100,000
CRV_00057995	Anne Blaschke	Associate Professor and Principal Investigator	Pilot Evaluation of the FilmArray® Childhood Systemic Infection (CSI) Panel	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00058156	Mohamed Salama	Professor and Principal Investigator	Microscopic Cellular Features of Whole Blood Samples	Techcyte	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00058175	Thomas Higgins	Professor and Co-Investigator	What happens on the back table? Viability of RIA graft as a function of time and temperature	Depuy Sythes	Income for Consulting	\$10,000-19,999
CRV_00058340	David Turok	Assistant Professor (Clinical) and Co-Investigator	Highly Effective Reversible Contraceptive Initiative – Salt Lake Stories: A Qualitative Study	Teva Women's Health	Employment	\$10,000-19,999
CRV_00059300	Mark Jensen	Student and Co-Investigator	Development and Initial Testing of Novel Silk-elastinlike Protein Polymers for Aneurysm Intervention	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00059352	James Hotaling	Assistant Professor and Co-Investigator	Validation study of urine flow rate monitoring with novel device: StreamDx.	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00059353	James Hotaling	Assistant Professor and Co-Investigator	StreamDx	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00059562	Sean Mulvihill	Associate Vice President and Principal Investigator	A Feasibility Study for the Early Detection of Pancreatic Cancer	N/A	Intellectual Property	\$10,000-19,999
CRV_00059582	Matthew Firpo	Research Associate Professor and Co-Investigator	A Feasibility Study for the Early Detection of Pancreatic Cancer	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00059746	Paul Bernstein	Professor and Principal Investigator	Natural History of Individuals with Retinal Degeneration due to Mutations in the CHM Gene	Spark Therapeutics	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00060157	Gabor Marth	Professor and Co-Investigator	Web tools to enhance physician-driven diagnostic interpretation of genomic patient data	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00060451	Edward Dudek	Professor and Principal Investigator	Anticonvulsant screening using chronic epilepsy models	Epitel	Income for Consulting	\$20,000-39,999
CRV_00060451	Edward Dudek	Professor and Principal Investigator	Anticonvulsant screening using chronic epilepsy models	Epitel	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00060574	Michael Deininger	Professor and Principal Investigator	A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement	Incyte	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00060653	Michael Tanana	Research Assistant Professor and Co-investigator	Iterative development of Computerized Motivational Interviewing Feedback.	Lyssn.io	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00060672	Geoffrey Miller	Adjunct Instructor and Co-investigator	Determination of serum L-carnitine levels pre, during, and post intravenous infusion of L-carnitine with varying infusion volumes.	Sports Medicine Research and Testing Laboratory	Employment	\$60,000-79,999
CRV_00060673	Geoffrey Miller	Adjunct Instructor and Co-investigator	Assessment of Biological Passport Profiles following an Ironman Event	Sports Medicine Research and Testing Laboratory	Employment	\$60,000-79,999
CRV_00060689	Zachary Imel	Associate Professor and Principal Investigator	DEVELOPMENT AND FEASIBILITY OF COMPUTER BASED FIDELITY MONITORING FOR MI.	Lyssn.io	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00060690	Zachary Imel	Associate Professor and Principal Investigator	Implementation of Technology-based Evaluation of Motivational Interviewing	Lyssn.io	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00060694	Zachary Imel	Associate Professor and Principal Investigator	Iterative development of Computerized Motivational Interviewing Feedback.	Lyssn.io	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00060700	Tibor Kovacovics	Professor (Clinical) and Principal Investigator	A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma	Amgen	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00060831	Jutta Deininger	Nurse Practitioner and Co-Investigator	Alliance Foundation Trials AFT-38>>A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Recept	Pfizer	Income for Consulting	\$10,000-19,999
CRV_00060893	Mark Yandell	Professor and Co-Investigator	Software for exploring all forms of genetic variation in any species	Fabric Genomics (Omicia)	Income for Consulting/Advisory Board	\$20,000-39,999
CRV_00060893	Mark Yandell	Professor and Co-Investigator	Software for exploring all forms of genetic variation in any species	Fabric Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00061132	Gabor Marth	Professor and Principal Investigator	IOBIO: Web-based, interactive tools for real-time analysis in genomic big data	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00061310	Aaron Quinlan	Associate Professor and Co-Investigator	IOBIO: Web-based, interactive tools for real-time analysis in genomic big data	Base2 Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00061317	Aaron Quinlan	Associate Professor and Principal Investigator	Software for exploring all forms of genetic variation in any species	Base2 Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00061343	Tibor Kovacovics	Professor (Clinical) and Principal Investigator	A Randomized, Double-blind, Placebo Controlled, Study of Venetoclax in Combination with Azacitidine VS Azacitidine in Treatment with NaÁÁÁÁÁÁve Elderly subjects with Acute Myeloid Leukemia who are ineligible for Standard Induction Therapy	Celgene	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00061593	James Hotaling	Assistant Professor and Principal Investigator	Stream Dx: accurate and efficient, point-of-care uroflowmetry for improved diagnosis, monitoring, and post-treatment evaluation of LUTS	StreamDx	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00061627	Jutta Deininger	Nurse Practitioner and Co-Investigator	Alliance Foundation Trials AFT – 05 >> PALLAS: PALbociclib CoLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (Pfizer	Income for Consulting	\$10,000-19,999
CRV_00061669	David Turok	Associate Professor (Clinical) and Principal Investigator	Midcareer Investigator Award in Patient-Oriented Research	Teva Women's Health	Employment	\$10,000-19,999
CRV_00061776	Michael Deininger	Professor and Principal Investigator	Novartis CABL001A2301>>A Phase 3, Multi-Center, Open-Label, Randomized Study Of Oral ABL001 Versus Bosutinib In Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML-CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00061776	Michael Deininger	Professor and Principal Investigator	Novartis CABL001A2301>>A Phase 3, Multi-Center, Open-Label, Randomized Study Of Oral ABL001 Versus Bosutinib In Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML-CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors	Novartis	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00061897	Joshua Cates	Research Computer Scientist and Co-Investigator	New 3D and 4D Image-Based Clinical Measures of Atrial Structural and Functional Remodeling in Atrial Fibrillation	Marrek, Inc	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00062080	Michael Tanana	Research Assistant Professor and Co-investigator	Implementation of Technology-Based Evaluation of Motivational Interviewing	Lyssn.io	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00062081	Zachary Imel	Associate Professor and Principal Investigator	Implementation of Technology-Based Evaluation of Motivational Interviewing	Lyssn.io	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00062097	Gabor Marth	Professor and Principal Investigator	Web tools for physician-driven diagnostic interpretation of genomic patient data	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00062488	Terry Box	Associate Professor (Clinical) and Co-Investigator	GS-US-384-1943: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis	Gilead	Income for Consulting/Education/Spreading	\$5,000-9,999
CRV_00062670	Michael Deininger	Professor and Co-Investigator	AbbVie M16-109>>A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination with Ruxolitinib in Subjects with Myelofibrosis Incorporating Amendments	Incyte	Income for Consulting/Advisory Board	\$10,000-19,999
CRV_00062901	Anne Blaschke	Associate Professor and Co-Investigator	RADICAL IIA: Evaluation of a Rapid Diagnostic Test for the Categorization of Acute Respiratory Illness	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00063164	Michael Kay	Professor and Co-Investigator	Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH Center)	Navigen	Income for Consulting	\$10,000-19,999
CRV_00063164	Michael Kay	Professor and Co-Investigator	Center for the Structural Biology of Cellular Host Elements in Egress, Trafficking, and Assembly of HIV (CHEETAH Center)	Navigen	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00063400	R. Lor Randall	Professor and Co-Investigator	A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath	Daiichi Sankyo	Income for Consulting	\$10,000-19,999
CRV_00063405	R. Lor Randall	Professor and Co-Investigator	Daiichi Sankyo PLX108-10>>A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN	Daiichi Sankyo	Income for Consulting	\$10,000-19,999
CRV_00063610	Lucinda Bateman	Faculty and Co-investigator	Using the UPDB to Increase Understanding of Chronic Fatigue Syndrome and Fibromyalgia	Bateman Home Health Center for Excellence	Employment	\$80,000-\$99,999
CRV_00063685	Howard Colman	Professor and Co-Investigator	Alliance A071601(CIRB)>>Phase II trial of BRAF/MEK inhibitors in papillary craniopharyngiomas	Hoffman La Roche/Genentech	Income for Consulting/Advisory Board	\$5,000-9,999
CRV_00064098	Stephen Summers	Assistant Professor and Co-Investigator	Stream Dx: accurate and efficient, point-of-care uroflowmetry for improved diagnosis, monitoring, and post-treatment evaluation of LUTS	StreamDx	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00064251	Gerald Gleich	Research Professor and Principal Investigator	GSK 205203: A multi-centre, open-label extension, safety study to describe the longterm clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622	GlaxoSmithKline	Income for Consulting	\$5,000-9,999
CRV_00064256	Gerald Gleich	Research Professor and Principal Investigator	A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asthma-201810	GlaxoSmithKline	Income for Consulting	\$5,000-9,999
CRV_00064263	Gerald Gleich	Research Professor and Principal Investigator	(GSK 201810) A multi-center, randomized, double-blind, placebo controlled, parallel group study to compare cessation versus continuation of long-term mepolizumab treatment in patients with severe eosinophilic asthma (201810)	GlaxoSmithKline	Income for Consulting	\$5,000-9,999
CRV_00064266	Gerald Gleich	Research Professor and Principal Investigator	GSK 204959: An open-label, single arm, repeat dose, multi-centre study to evaluate the use of an autoinjector for the subcutaneous administration of mepolizumab in subjects with severe eosinophilic asthma (Study 204959)	GlaxoSmithKline	Income for Consulting	\$5,000-9,999
CRV_00064292	Scott Summers	Professor and Principal Investigator	Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases	Centaurus Therapeutics	Income for Consulting	\$10,000-19,999
CRV_00064292	Scott Summers	Professor and Principal Investigator	Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases	Centaurus Therapeutics	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00064808	Robert Schlaberg	Assistant Professor and Co-Investigator	Metagenomics Approach to the Evaluation of Kawasaki Disease	IDbyDNA	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$60,000-79,999
CRV_00064888	Aaron Quinlan	Associate Professor and Principal Investigator	A powerful web-based discovery platform for rare disease genomics	Base2 Genomics	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.

CRV_00065014	Brook Martin	Research Associate Professor and Principal Investigator	The Influence of an expanded bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	Statix, LLC	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00065016	Brook Martin	Research Associate Professor and Principal Investigator	Influence of an expanded mandatory bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	Statix, LLC	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00065477	Carol Bruggers	Professor and Co- Investigator	Self-Management Epilepsy Questionnaire	Epicadence	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00066124	Gerald Gleich	Research Professor and Principal Investigator	A multi-centre, open-label extension, safety study of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622, Protocol no. 205203	GlaxoSmithKline	Income for Consulting	\$5,000-9,999
CRV_00066429	Pegah Afra	Associate Professor and Principal Investigator	Self-Management Epilepsy Questionnaire	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00066430	Matthew Sweney	Assistant Professor (Clinical) and Co-Investigator	Self-Management Epilepsy Questionnaire	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00066434	Kent Bachus	Research Professor and Co-Investigator	Percutaneous Osseointegrated Docking System for Above Elbow Amputees...IPA Castolene	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00066439	Sean Runnels	Assistant Professor (Clinical) and Principal Investigator	THE EFFECTS OF A UNIQUE COLOR ZONE SYSTEM ON ENDOTRACHEAL TUBE DEPTH CONTROL DURING EMERGENCY INTUBATIONS WITH VIDEO LARYNGOSCOPY IN AIRWAY MANNEQUINS	Through the cords	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00066547	Peter Stevens	Professor and Principal Investigator	Guided growth for proximal tibial recurvatum	Orthofix	Royalty Income from Intellectual Property	>\$100,000
CRV_00066629	Kent Bachus	Research Professor and Principal Investigator	Biomechanical Testing of Orthopaedic Devices Using Decedent Tissue Models	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00066990	Kent Bachus	Research Professor and Principal Investigator	The variability of the residual bone and soft tissues of amputated extremities following traumatic amputation	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00067454	Florian Solzbacher		Plasma-assisted atomic layer deposition of alumina and Parylene-C bi-layer encapsulation	Blackrock Microsystems	Income for Consulting/Intellectual Property	>\$100,000
CRV_00067455	Florian Solzbacher	Professor and Co-Investigator	Revolutionizing Utah Array using Nanotechnology to Enhance Efficacy and Longevity	Blackrock Microsystems	Income for Consulting/Intellectual Property	>\$100,000
CRV_00067821	Tibor Kovacovics	Professor (Clinical) and Co-Investigator	Amgen 20150161>>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia	Celgene	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00067823	Tibor Kovacovics	Professor (Clinical) and Co-Investigator	LLS BAML-16-001-M1>> (WIRB) A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)	Celgene	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00068559	C. Matthew Peterson	Professor and Co-Investigator	Development of novel polymer-based, nanotechnology, delivery systems for targeted delivery to overcome drug resistance in ovarian cancer and gynecological malignancies utilizing genital tract (vaginal, cervical, endometrial, peritoneal and ovarian) tissue	TheraTarget	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00068823	K-T VARLEY	Assistant Professor and Co-Investigator	Cancer Genetics Study	Kailos Genetics	Income for Consulting/Intellectual Property	\$20,000-39,999
CRV_00069196	Robert Burks	Professor and Co-Investigator	Long Term Patient Reported Outcomes for the Shoulder and Elbow Population	KATOR	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00069201	Anne Blaschke	Associate Professor and Principal Investigator	Pilot Evaluation of the FilmArray Childhood Systemic Infection (CSI) Panel	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00069213	Mark Yandell	Professor and Co-Investigator	A Community Driven Framework for Genome Based Clinical Diagnostics	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069222	Mark Yandell	Professor and Principal Investigator	VAAS+ : Tool for variant prioritization, risk assessment and disease-gene finding	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999

CRV_00069223	Mark Yandell	Professor and Co-Investigator	Integrating Genomic and Clinical Approaches to Sudden Death in the Young	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069226	Mark Yandell	Professor and Co-Investigator	Bridging the Gap between Genomics and Clinical Outcomes in CHD	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069227	Mark Yandell	Professor and Co-Investigator	PEDIATRIC CARDIAC GENOMICS CONSORTIUM: CONGENITAL HEART DISEASE GENETIC NETWORK STUDY (CHD GENES)	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069229	Mark Yandell	Professor and Co-Investigator	Biological Determinants of Brain Variation in Autism	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069233	Mark Yandell	Professor and Co-Investigator	Pediatric Cardiology Genotype-Phenotype Core	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069234	Mark Yandell	Professor and Co-Investigator	Genetic, Molecular, and Cellular Mechanisms Regulating Development of Congenital Diaphragmatic Hernias	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069235	Mark Yandell	Professor and Co-Investigator	Genetics Of Autism	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069236	Mark Yandell	Professor and Co-Investigator	Utah Genome Project	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00069474	Jeremy Gilliland	Assistant Professor and Co-Investigator	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	Smith & Nephew	Income for Consulting	\$5,000-9,999
CRV_00069699	Robert Tashjian	Professor and Principal Investigator	Efficacy of the BioWick SureLock Implant for the Reattachment of Soft Tissue to Bone in Subject Undergoing Rotator Cuff Repairs	Zimmer Biomet	Income for Consulting	\$10,000-19,999
CRV_00069707	Robert Tashjian	Professor and Principal Investigator	Functional and Radiographic Outcomes after Shoulder Surgery	Shoulder Innovations, Wright Medical Technology, Zimmer Biomet	Income for Consulting/Equity Interest	\$40,000-59,999; \$10,000-19,999; \$10,000-19,999
CRV_00069745	Djordje Atanackovic	Associate Professor and Co-Investigator	Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone, Versus Lenalidomide, Bortezomib, and Dexamethasone, in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High Dose Chemotherapy, Autologous Stem Cell Transplantation	Millennium Pharmaceuticals	Income for Consulting/Education/Sp speaking	\$10,000-19,999
CRV_00069763	Djordje Atanackovic	Associate Professor and Co-Investigator	OSU 14031/NCI 9603>>Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma	Amgen/Onyx	Income for Consulting/Speaking	\$5,000-9,999
CRV_00069772	Djordje Atanackovic	Associate Professor and Co-Investigator	Janssen 54767414MMY2004>>Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible	Janssen Pharmaceutical Inc	Income for Consulting	\$10,000-19,999

CRV_00069808	Scott Summers	Professor and Principal Investigator	The Role of Ceramides in Skeletal Muscle	Centaurus Therapeutics	Income for Consulting/Equity Interest/Employment	\$20,000-39,999
CRV_00069918	Scott Summers	Professor and Principal Investigator	Role of Ceramides in Skeletal Muscle	Centaurus Therapeutics	Income for Consulting/Equity Interest/Employment	\$20,000-39,999
CRV_00070112	Gerald Gleich	Research Professor and Principal Investigator	Study 200622: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic syndrome	GlaxoSmithKline	Income for Consulting	\$5,000-9,999
CRV_00070201	Djordje Atanackovic	Associate Professor and Co-Investigator	Roche Genentech GO29695>>A Phase Ib Study Of The Safety And Pharmacokinetics Of Atezolizumab (Anti Pd L1 Antibody) Alone Or In Combination With An Immunomodulatory Drug and/or Daratumumab In Patients With Multiple Myeloma (Relapsed/Refractory And Post Au	Janssen Pharmaceutical Inc	Income for Consulting	\$10,000-19,999
CRV_00070406	Tibor Kovacsovics	Professor (Clinical) and Principal Investigator	OSU 14031/NCI 9603>>Pilot Trial Evaluating the Combination of Reolysin and Carfilzomib in Multiple Myeloma	Amgen	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00070461	George Rodgers	Professor and Principal Investigator	BIV 0-3 Cardina: A Pivotal Open-Label Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease who have a Recent History of Blood Transfusion (Cardina)	Bioverativ	Income for Consulting	\$20,000-39,999
CRV_00070468	George Rodgers	Professor and Principal Investigator	BIV 0-4 Cadenza A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WITHOUT A RECENT HISTORY OF BLOOD TRANSFUSION	Bioverativ	Income for Consulting	\$20,000-39,999
CRV_00070557	Djordje Atanackovic	Associate Professor and Principal Investigator	A PHASE Ib STUDY OF THE SAFETY AND PHARMACOKINETICS OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ALONE OR IN COMBINATION WITH AN IMMUNOMODULATORY DRUG AND/OR DARATUMUMAB IN PATIENTS WITH MULTIPLE MYELOMA	Janssen Pharmaceutical Inc	Income for Consulting	\$10,000-19,999
CRV_00070987	Dennis Parker	Professor and Co-Investigator	Validation and translation of a non-invasive, MR-guided breast cancer therapy	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00070993	Allison Payne	Research Associate Professor and Principal Investigator	Validation and translation of a non-invasive, MR-guided breast cancer therapy	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00071050	Mark Yandell	Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF BREAST CANCER	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00071083	Stephen Summers	Assistant Professor and Principal Investigator	Study of urine flow rate monitoring with novel device: Stream Dx.	StreamDx	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00071085	Bryan Jones	Research Associate Professor and Principal Investigator	Retinal Circuitry	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00071172	Harry Hill	Professor and Principal Investigator	Interferon Gamma (IFN-gamma, Actimmune) Effects on Variant X-Linked and Autosomal Recessive Chronic Granulomatous Disease (CDG)	Vidara Therapeutics	Income for Speaking	\$5,000-9,999
CRV_00071192	Leslie Jerominski	Sr Laboratory Specialist and Co-Investigator	Genetic risk factors in suicide and depression	Janssen Pharmaceutical Inc	Employment	\$5,000-9,999
CRV_00071451	Nassir Marrouche	Professor and Principal Investigator	Women's Only Heart Research Initiative (WOHRI): Structural and Biometric Factors Influencing Heart Disease in Women	Cardiac Designs and Wavelet Health	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00071834	Douglas Sborov	Assistant Professor (Clinical) and Co-Investigator	Onyx CFZ013 >> Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma	Celgene	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00071839	Tibor Kovacsovics	Professor (Clinical) and Co-Investigator	A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia	Amgen	Income for Consulting/Education/Sp eaking	\$10,000-19,999

CRV_00071953	Mark Yandell	Professor and Co-Investigator	Whole Genome Sequencing-Based Discovery of Genes for Diabetic Kidney Disease	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00072047	Tibor Kovacs	Professor (Clinical) and Co-Investigator	Celgene ACE-MM-104 >> A Phase 1b Multicenter, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of ACY-1215 (Ricolinostat) in Combination with Pomalidomide and Low-dose Dexamethasone in Patients with	Celgene	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00072071	George Rodgers	Professor and Principal Investigator	A PIVOTAL, OPEN-LABEL, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BIVV009 IN PATIENTS WITH PRIMARY COLD AGGLUTININ DISEASE WHO HAVE A RECENT HISTORY OF BLOOD TRANSFUSION	Bioerativ	Income for Consulting	\$20,000-39,999
CRV_00072165	Henry White	Professor and Principal Investigator	exonuclease-nanopore platform (RNA)	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00072556	Natalie Silverton	Assistant Professor (Clinical) and Principal Investigator	Noninvasive measurements of renal perfusion during cardiac surgery	KSCube	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00072772	Gabor Marth	Professor and Co-Investigator	Web tools to enhance physician-driven diagnostic interpretation of genomic patient data: DNA sequencing and analysis.	Frameshift Labs, LLC	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073006	Djordje Atanackovic	Associate Professor and Co-Investigator	Janssen 54767414AMY3001>>A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBORd) Compared with CyBORd Alone in Newly Diagnosed Systemic AL Amyloidosis.	Janssen Pharmaceutical Inc	Income for Consulting	\$10,000-19,999
CRV_00073182	Anthony Donato	Associate Professor and Principal Investigator	Novel Methodology for Identification of Senolytics that Reduce Age-Related Disease and Dysfunction	Recursion Pharmaceuticals	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073209	Mei Yee Koh	Assistant Professor and Principal Investigator	A novel approach for the selective inhibition of HIF-2a in kidney cancer	Kuda Therapeutics	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073315	Kai Kuck	Professor and Co-Investigator	Noninvasive measurements of renal perfusion during cardiac surgery	KSCube	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073456	Kai Kuck	Professor and Co-Investigator	Monitor to Detect Kidney Risk	KSCube	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073457	Natalie Silverton	Assistant Professor (Clinical) and Principal Investigator	Monitor to Detect Kidney Risk	KSCube	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073736	Erik Jorgensen	Professor and Co-Investigator	Regulation of nutrient transporters	Bruker Materials Group	Income from Consulting/Intellectual Property	\$10,000-19,999
CRV_00073748	Pouya Hadipour	Graduate Research Assistant and Co-Investigator	The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00073806	Jeremiah Alt	Assistant Professor and Principal Investigator	A NOVEL GLYCOSAMINOGLYCAN-BASED THERAPEUTIC FOR CHRONIC RHINOSINUSITIS	Glycomira Therapeutics	Equity Interest	\$10,000-19,999
CRV_00074000	Jeremiah Alt	Assistant Professor and Principal Investigator	Sinonasal Tissue Repository	Glycomira Therapeutics	Equity Interest	\$10,000-19,999
CRV_00074145	Gerald Krueger	Professor and Co-Investigator	I4V-MC-JAIW - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis	Eli Lilly	Income for Consulting/Education/Spreading	\$10,000-19,999
CRV_00074155	Gerald Krueger	Professor and Co-Investigator	Corrona-PSO-500 Corrona Psoriasis Registry	Abbvie, Eli Lilly, Johnson & Johnson, and Novartis	Income for Consulting/Education/Spreading	\$10,000-19,999; \$10,000-19,999; \$20,000-39,999; \$20,000-39,999
CRV_00074162	Hamid Ghandehari	Professor and Principal Investigator	The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00074311	Gerald Krueger	Professor and Co-Investigator	Psoriatic Arthritis Research Consortium (PARC)	Abbvie, Eli Lilly, Johnson & Johnson, and Novartis	Income for Consulting/Education/Spreading	\$10,000-19,999; \$10,000-19,999; \$20,000-39,999; \$20,000-39,999

CRV_00074367	Gerald Krueger	Professor and Co-Investigator	I6T-MC-AMAK - A Multicenter Study with a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients with Moderate-to-Se	Eli Lilly	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00074585	Karen Eilbeck	Professor and Co-Investigator	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	IDbyDNA	Income for Consulting/Intellectual Property	\$5,000-9,999
CRV_00074587	Mark Yandell	Professor and Co-Investigator	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00074587	Mark Yandell	Professor and Co-Investigator	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	IDbyDNA	Equity Interest/Intellectual Property	\$5,000-9,999
CRV_00074592	Mark Yandell	Professor and Co-Investigator	ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms [IMP	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00074627	Gerald Krueger	Professor and Co-Investigator	PS0008 – A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to	Abbvie	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00074704	KYLE ISAACSON	Graduate Research Assistant and Co-Investigator	The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00074705	Robert Tashjian	Professor and Principal Investigator	Efficacy of the BioWick™ SureLock™ Implant for the Reattachment of Soft Tissue to Bone in Subjects Undergoing Rotator Cuff Repairs	Zimmer Biomet	Income for Consulting	\$10,000-19,999
CRV_00074854	Jeremy Gilliland	Assistant Professor and Principal Investigator	Retrospective Investigation of Patient Outcomes Following Total Hip Arthroplasty for Hip Fractures	DJO Surgical, Medcata, Smith & Nephew	Income for Consulting/Education/Sp eaking	\$10,000-19,999; \$10,000-19,999;\$10,000-19,999
CRV_00074861	Jeremy Gilliland	Assistant Professor and Principal Investigator	Safety Study of Percutaneous Osseointegrated Implants for Prosthetic Attachment	DJO Surgical	Income for Consulting	\$10,000-19,999
CRV_00074878	Jeremy Gilliland	Assistant Professor and Principal Investigator	INTRAOPERATIVE DATA COLLECTION FOR THE USE OF A NOVEL DIGITAL FLUOROSCOPIC GRID	OrthoGrid Technologies	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00074880	Rock Hadley	Assistant Professor and Co-Investigator	Evaluation of Research Hardware and Software to Improve Magnetic Resonance (MR) Imaging and Spectroscopy with Human Subjects	#N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00074890	Mark Jensen	Student and Co-Investigator	The Hemocompatibility Study of Silica Nanoparticles as a function of Size and Surface Properties	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00074906	Mark Yandell	Professor and Co-Investigator	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00074911	Mark Yandell	Professor and Co-Investigator	Familial kinship analysis in patients with Mullerian anomalies	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00074950	Edward Gilbert	Professor and Co-Investigator	MOMENTUM 3 Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy with HeartMate 3	Abbott Laboratories	Research (non-OSP)	\$40,000-59,999
CRV_00074968	Feng Liu	Professor and Principal Investigator	Testing lifeE's samples of electrothermal coating	LIFE-E	Equity Interest	\$5,000-9,999
CRV_00075015	Douglas Sborov	Assistant Professor (Clinical) and Co-Investigator	Sanofi TCD14079>>A Phase 1b Study of SAR650984 (isatuximab) in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma SAR650984 / TCD14079)	Celgene	Income for Consulting/Education/Sp eaking	\$5,000-9,999

CRV_00075164	Jonathan Tward	Associate Professor and Principal Investigator	A Retrospective Study of Prolaris for the Prediction of Progression in Men Treated with Modern External Beam Radiation Therapy for Prostate Cancer	Myriad Genetics	Income for Consulting	\$5,000-9,999
CRV_00075233	James Hotaling	Assistant Professor and Co-Investigator	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	NanoNC	Equity Interest	<\$5,000
CRV_00075234	Bruce Gale	Professor and Principal Investigator	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	NanoNC	Equity Interest	\$40,000-59,999
CRV_00075308	Peter Stevens	Professor and Co-Investigator	Growth Modulation in Achondroplasia	N/A	Royalty Income from Intellectual Property	>\$100,000
CRV_00075529	Swomitra Mohanty	Associate Professor and Principal Investigator	EVALUATION OF A NOVEL BREATH SENSOR FOR RAPID, LOW-COST DIAGNOSIS OF TUBERCULOSIS IN CHILDREN	N/A	Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00075563	Philip Bernard	Associate Professor and Co-Investigator	GENETIC EPIDEMIOLOGY OF BREAST CANCER	Bioclassifier	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00075628	Michael YU	Associate Professor and Principal Investigator	TARGETING COLLAGEN MECHANICAL DAMAGE USING COLLAGEN HYBRIDIZING PEPTIDES	3Helix	Equity Interest/Intellectual Property	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00075641	Martin McMahon	Professor and Principal Investigator	ELUCIDATING TUMOR PROGRESSION FACTORS IN MAPK-DRIVEN LUNG CANCERS	#N/A	Intellectual Property	\$10,000-19,999
CRV_00075828	Robert Tashjian	Professor and Co-Investigator	Optimal Treatment of Glenoid Retroversion in Shoulder Arthroplasty	Wright Medical Technology	Income for Consulting/Equity Interest	\$80,000-\$99,999
CRV_00075882	Mark Yandell	Professor and Co-Investigator	A Feasibility Study for the Early Detection of Pancreatic Cancer	Fabric Genomics	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$20,000-39,999
CRV_00075909	Philipp Taussky	Associate Professor and Principal Investigator	Prospective Study on Embolization of Intracranial Aneurysms with Pipeline Embolization Device (PREMIER)	Covidien	Income for Consulting	\$40,000-59,999
CRV_00076181	Tim Jenkins	Associate Professor and Principal Investigator	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	NanoNC	Equity Interest/Intellectual Property	\$5,000-9,999
CRV_00076215	Michael Deininger	Professor and Principal Investigator	A Phase 3, Multi-Center Open -Label, Randomized Study of Oral ABL001 versus Bosutinib in Patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP), Previously Treated with 2 or more Tyrosine Kinase Inhibitors.	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076219	Michael Deininger	Professor and Principal Investigator	Stopping Tyrosine Kinase Inhibitors in CML Patients	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076232	Michael Deininger	Professor and Principal Investigator	STOPPING TYROSINE KINASE INHIBITORS IN CML PATIENTS	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076236	Michael Deininger	Professor and Principal Investigator	Stopping Tyrosine Kinase Inhibitors in CML Patients	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076237	Michael Deininger	Professor and Principal Investigator	Therapeutic Drug Monitoring of Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Therapy using Scalp Hair Concentrations	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076238	Michael Deininger	Professor and Principal Investigator	Stopping Tyrosine Kinase Inhibitors in CML Patients	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076276	Michael Deininger	Professor and Principal Investigator	Medical College of Wisconsin>>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST study)	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076280	Michael Deininger	Professor and Principal Investigator	THERAPEUTIC DRUG MONITORING OF CHRONIC MYELOID LEUKEMIA PATIENTS ON TYROSINE KINASE INHIBITOR THERAPY USING SCALP HAIR CONCENTRATIONS	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076291	Michael Deininger	Professor and Principal Investigator	Pfizer AV001>>A Multicenter Phase 3, Randomized, Open-Label Study of Bosutinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999

CRV_00076292	Michael Deininger	Professor and Principal Investigator	Novartis CABL001A2301>>A Phase 3, Multi-Center, Open-Label, Randomized Study Of Oral ABL001 Versus Bosutinib In Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML-CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors	Pfizer	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076322	Gerald Krueger	Professor and Co-Investigator	ABBVIE PSORIASIS RESEARCH FELLOWSHIP	Abbvie	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076520	Gerald Krueger	Professor and Co-Investigator	I1F-MC-RHCD - Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab, in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis	Eli Lilly	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00076787	Gerald Krueger	Professor and Co-Investigator	M16-766 - A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis who are Candidates for Systemic Therapy	Abbvie	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00077011	ALAN MORRIS	Professor and Co-Investigator	University of Utah Atrial Fibrillation Database: AFIB	Marrek, Inc	Equity Interest	Value cannot be readily determined through reference to public prices or other reasonable measures of fair market value.
CRV_00077016	Douglas Carrell	Professor and Principal Investigator	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	NanoNC	Equity Interest/Intellectual Property	<\$5,000
CRV_00077037	Gerald Krueger	Professor and Co-Investigator	I4V-MC-JAIX - A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Moderate to Severe Atopic Dermatitis	Eli Lilly	Income for Consulting/Education/Sp eaking	\$10,000-19,999
CRV_00077276	Karen Eilbeck	Professor and Co-Investigator	Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collection Study	IDbyDNA	Income for Consulting/Intellectual Property	\$5,000-9,999
CRV_00077278	Mark Yandell	Professor and Co-Investigator	Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collection Study	IDbyDNA	Equity Interest/Intellectual Property	\$5,000-9,999
CRV_00077398	Robert Schlaberg	Assistant Professor and Co-Investigator	METAGENOMICS APPROACH TO THE EVALUATION OF KAWASAKI DISEASE: A MULTICENTER PILOT STUDY	IDbyDNA	Income for Consulting/Advisory Board/Equity Interest/Intellectual Property	\$60,000-79,999
CRV_00077671	Jared Thorley	Nurse Practitioner and Co-Investigator	Exelixis XL184-021>>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors	Exelixis	Income for Speaking	\$10,000-19,999
CRV_00077672	Julia Batten	Nurse Practitioner and Co-Investigator	Exelixis XL184-021>>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors	Exelixis	Income for Speaking	\$10,000-19,999
CRV_00077677	Robert Tashjian	Professor and Co-Investigator	Kator Anchor Performance Evaluation for Rotator Cuff Repair	KATOR	Equity Interest	\$40,000-59,999
CRV_00077748	Robert Burks	Professor and Co-Investigator	Kator Anchor Performance Evaluation for Rotator Cuff Repair	KATOR	Equity Interest	<\$5,000
CRV_00077846	Jared Thorley	Nurse Practitioner and Co-Investigator	Cabozantinib plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)	Exelixis	Income for Speaking	\$10,000-19,999
CRV_00077847	Julia Batten	Nurse Practitioner and Co-Investigator	Cabozantinib plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab)	Exelixis	Income for Speaking	\$10,000-19,999
CRV_00078130	Douglas Sborov	Assistant Professor (Clinical) and Co-Investigator	Merck MK-3475-185>> A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185).	Celgene	Income for Consulting/Education/Sp eaking	\$5,000-9,999
CRV_00078474	MARY KAY HARPER-IRELAND	Research Staff and Co-Investigator	EXPLORING THE CHEMISTRY OF MARINE INVERTEBRATE ORGANISMS FOR DRUG DISCOVERY AND CHEMOTAXONOMY	Sirenas	Income for Consulting	\$10,000-19,999